department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Iluvien · pharmadog

pharmadog
drugs
Iluvien

drug

patient view →

fluocinolone acetonide SR

Marketedupdated 2mo ago

by Alimera Sciences Inc

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 11 approved and 6 investigational indications.

indications

investigational

Diabetic Macular Edema

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Iluvien

generic

fluocinolone acetonide

MOA

Glucocorticoid receptor agonist

indication

Diabetic Macular Edema

phase

marketed

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov

last refreshed 56m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Aug 12, 2027

~1.1 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (4)

Nov 7, 2028formulationUS 98490272.3y
Jan 12, 2028formulationUS 79981081.5y
Aug 12, 2027formulationUS 88712411.1y
Aug 12, 2027formulationUS 88712411.1y

🐶 often sniffed alongside

top 6

tagApproval8 co-mentions · 4 sources
drugfluocinolone acetonide ER5 co-mentions · 5 sources
drugfluocinolone acetonide5 co-mentions · 5 sources
drugRetisert5 co-mentions · 5 sources
companySun Pharmaceutical Industries Ltd1 co-mentions · 1 sources
tagRecall1 co-mentions · 1 sources

Trials studying fluocinolone acetonide SR

phase3Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathyrecruitingn=600
phase4Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitisactive not recruitingn=125
phase4Open Label Trial Studying the Safety and Effectiveness of ILUVIEN® (190μg) in Children and Adolescents, Who Have Recurrent Non-infectious Uveitis Affecting the Posterior Segment of the Eye.recruitingn=25
phase4A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)active not recruitingn=300